BUFFALO GROVE, Ill., Dec. 31, 2021 (GLOBE NEWSWIRE) — BIOLIFE4D Corporation today announced that it intends to submit a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission in early 2022 for a proposed underwritten public offering of its common stock. The number of shares of common stock to be sold and the price range for the proposed offering have not been determined. The offering is subject to market and other conditions, including the effectiveness of the registration statement to be filed under the Securities Act of 1933, as amended (the “Securities Act”).